Signs Licensing and Supply Agreement with Pharmasyntez - Orchid Pharma Ltd

Code BSE: 524372 NSE:

Orchid Pharma Signs 1Licensing and Supply Agreement with Pharmasyntez to Commercialize 1Exblifep (Cefepime/Enmetazobactam) in Russia. Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form. The partnership represents a potential opportunity of approximately USD 178 million over the first 10 years, reflecting the scale of unmet clinical need and the significant hospital procurement volumes in the Russian market.